Estudo randomizado | Tirzepatida subcutânea adicionada a insulina glargina titulada melhora o controle glicêmico de pacientes com diabetes tipo 2.
10 Fev, 2022 | 13:49hEffect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Tirzepatide for Patients With Type 2 Diabetes – JAMA
Comentário: SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D – AJMC
Conteúdos relacionados: